Ironwood Wealth Management LLC. Sells 864 Shares of Pfizer Inc. (NYSE:PFE)

Ironwood Wealth Management LLC. decreased its holdings in Pfizer Inc. (NYSE:PFE) by 2.4% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 34,527 shares of the biopharmaceutical company’s stock after selling 864 shares during the period. Ironwood Wealth Management LLC.’s holdings in Pfizer were worth $994,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of PFE. Moneta Group Investment Advisors LLC raised its stake in Pfizer by 89,592.7% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after buying an additional 160,963,976 shares in the last quarter. Norges Bank bought a new position in Pfizer in the fourth quarter worth approximately $3,150,472,000. Charles Schwab Investment Management Inc. raised its stake in Pfizer by 10.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock worth $3,161,261,000 after buying an additional 9,393,992 shares in the last quarter. Morgan Stanley raised its stake in Pfizer by 10.3% in the fourth quarter. Morgan Stanley now owns 79,499,361 shares of the biopharmaceutical company’s stock worth $4,073,547,000 after buying an additional 7,419,929 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new position in Pfizer in the first quarter worth approximately $311,238,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.1 %

Shares of Pfizer stock opened at $26.34 on Friday. The firm has a 50-day simple moving average of $27.30 and a two-hundred day simple moving average of $28.98. The company has a market cap of $149.12 billion, a P/E ratio of 73.15, a price-to-earnings-growth ratio of 1.19 and a beta of 0.61. Pfizer Inc. has a fifty-two week low of $25.61 and a fifty-two week high of $41.79. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The business had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company’s revenue was down 41.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.14 earnings per share. As a group, equities analysts predict that Pfizer Inc. will post 2.22 earnings per share for the current fiscal year.

Analysts Set New Price Targets

PFE has been the topic of several analyst reports. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Truist Financial dropped their price objective on shares of Pfizer from $42.00 to $36.00 and set a “buy” rating on the stock in a report on Thursday, December 14th. Barclays dropped their price objective on shares of Pfizer from $34.00 to $28.00 and set an “equal weight” rating on the stock in a report on Thursday, December 14th. UBS Group dropped their price objective on shares of Pfizer from $34.00 to $27.00 and set a “neutral” rating on the stock in a report on Thursday, December 14th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Monday, April 1st. Twelve analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $36.88.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.